Trial Profile
An Early Evaluation of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin in the US
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2016
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 13 Feb 2016 New trial record